Befesa S.A. : Target reached
SELL
Repli_rebond
Stop-loss triggered
Entry price | Target | Stop-loss | Potential |
---|
€36 |
€29.75 |
€40 |
+17.36% |
---|
After the strong price increase that has been seen over the past few weeks, it appears opportune to anticipate a correction phase for shares in Befesa S.A., as the resistance around 38.2 EUR approaches.
Strengths● Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses● Technically, the stock approaches a strong medium-term resistance at EUR 38.2.
● The group shows a rather high level of debt in proportion to its EBITDA.
● The company's earnings releases usually do not meet expectations.
● The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
● For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
● For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
● For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.